MedTrace Logo

Use of ACTIMMUNE in Patients With ADO2

NCT02584608 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2021-01-08

Study results available
· View outcomes & findings →

Summary

This study is an open label use of ACTIMMUNE for patients with Autosomal Dominant Osteopetrosis Type 2(ADO2). Effects of treatment will be evaluated after 14 weeks on ACTIMMUNE by bone resorption markers. This study will treat 12 patients with ADO2 recruited from Indiana University and Riley Hospital for Children at Indiana University Health.

Conditions

  • Autosomal Dominant Osteopetrosis Type 2

Interventions

DRUG

ACTIMMUNE

Sponsors & Collaborators

  • Horizon Pharma Ireland, Ltd., Dublin Ireland

    collaborator INDUSTRY

  • Indiana University

    lead OTHER

Principal Investigators

  • Michael J Econs, MD · Indiana University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-01
Primary Completion
2019-11-12
Completion
2019-11-12

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02584608 on ClinicalTrials.gov